
Opinion|Videos|April 8, 2024
Safety Profile of GVHD Treatment Options
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















